These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 25881897)

  • 1. Synthesis of a high specific activity methyl sulfone tritium isotopologue of fevipiprant (NVP-QAW039).
    Luu VT; Goujon JY; Meisterhans C; Frommherz M; Bauer C
    J Labelled Comp Radiopharm; 2015 May; 58(5):188-95. PubMed ID: 25881897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy.
    Sykes DA; Bradley ME; Riddy DM; Willard E; Reilly J; Miah A; Bauer C; Watson SJ; Sandham DA; Dubois G; Charlton SJ
    Mol Pharmacol; 2016 May; 89(5):593-605. PubMed ID: 26916831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.
    Erpenbeck VJ; Popov TA; Miller D; Weinstein SF; Spector S; Magnusson B; Osuntokun W; Goldsmith P; Weiss M; Beier J
    Pulm Pharmacol Ther; 2016 Aug; 39():54-63. PubMed ID: 27354118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.
    Erpenbeck VJ; Vets E; Gheyle L; Osuntokun W; Larbig M; Neelakantham S; Sandham D; Dubois G; Elbast W; Goldsmith P; Weiss M
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):306-13. PubMed ID: 27310331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Same Target, Different Therapeutic Outcomes: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and Asthma.
    Issahaku AR; Agoni C; Soremekun OS; Kubi PA; Kumi RO; Olotu FA; Soliman MES
    Comb Chem High Throughput Screen; 2019; 22(8):521-533. PubMed ID: 31538888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro.
    Pearson D; Weiss HM; Jin Y; Jaap van Lier J; Erpenbeck VJ; Glaenzel U; End P; Woessner R; Eggimann F; Camenisch G
    Drug Metab Dispos; 2017 Jul; 45(7):817-825. PubMed ID: 28442499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic approaches to site selective deuterium incorporation in a novel CRTh2 receptor antagonist clinical candidate.
    Sandham DA; Page CJ
    J Labelled Comp Radiopharm; 2014 Mar; 57(3):175-7. PubMed ID: 24452929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indole-3-acetic acid antagonists of the prostaglandin D2 receptor CRTH2.
    Armer RE; Ashton MR; Boyd EA; Brennan CJ; Brookfield FA; Gazi L; Gyles SL; Hay PA; Hunter MG; Middlemiss D; Whittaker M; Xue L; Pettipher R
    J Med Chem; 2005 Oct; 48(20):6174-7. PubMed ID: 16190744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fevipiprant, a DP
    Shamri R; Dubois G; Erpenbeck VJ; Mankuta D; Sandham DA; Levi-Schaffer F
    Clin Exp Allergy; 2019 Feb; 49(2):255-257. PubMed ID: 30379368
    [No Abstract]   [Full Text] [Related]  

  • 10. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
    Gonem S; Berair R; Singapuri A; Hartley R; Laurencin MFM; Bacher G; Holzhauer B; Bourne M; Mistry V; Pavord ID; Mansur AH; Wardlaw AJ; Siddiqui SH; Kay RA; Brightling CE
    Lancet Respir Med; 2016 Sep; 4(9):699-707. PubMed ID: 27503237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fevipiprant, a selective prostaglandin D
    Hardman C; Chen W; Luo J; Batty P; Chen YL; Nahler J; Wu Y; Pavord ID; Erpenbeck VJ; Sandham DA; Xue L; Ogg G
    J Allergy Clin Immunol; 2019 Jun; 143(6):2329-2333. PubMed ID: 30825466
    [No Abstract]   [Full Text] [Related]  

  • 12. Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.
    Sandham DA; Arnold N; Aschauer H; Bala K; Barker L; Brown L; Brown Z; Budd D; Cox B; Docx C; Dubois G; Duggan N; England K; Everatt B; Furegati M; Hall E; Kalthoff F; King A; Leblanc CJ; Manini J; Meingassner J; Profit R; Schmidt A; Simmons J; Sohal B; Stringer R; Thomas M; Turner KL; Walker C; Watson SJ; Westwick J; Willis J; Williams G; Wilson C
    Bioorg Med Chem; 2013 Nov; 21(21):6582-91. PubMed ID: 24021582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP
    Sandham DA; Barker L; Brown L; Brown Z; Budd D; Charlton SJ; Chatterjee D; Cox B; Dubois G; Duggan N; Hall E; Hatto J; Maas J; Manini J; Profit R; Riddy D; Ritchie C; Sohal B; Shaw D; Stringer R; Sykes DA; Thomas M; Turner KL; Watson SJ; West R; Willard E; Williams G; Willis J
    ACS Med Chem Lett; 2017 May; 8(5):582-586. PubMed ID: 28523115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981.
    Luker T; Bonnert R; Brough S; Cook AR; Dickinson MR; Dougall I; Logan C; Mohammed RT; Paine S; Sanganee HJ; Sargent C; Schmidt JA; Teague S; Thom S
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6288-92. PubMed ID: 21944852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin D₂ receptor CRTH2 antagonists for the treatment of inflammatory diseases.
    Chen JJ; Budelsky AL
    Prog Med Chem; 2011; 50():49-107. PubMed ID: 21315928
    [No Abstract]   [Full Text] [Related]  

  • 16. Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3.
    Kulkarni S; Poller B; Drollmann A; Shah B; Gray C; Greco E; Rahmanzadeh G; Hanna I; Weiss HM
    Pulm Pharmacol Ther; 2022 Feb; 72():102097. PubMed ID: 34800680
    [No Abstract]   [Full Text] [Related]  

  • 17. Fevipiprant in the treatment of asthma.
    White C; Wright A; Brightling C
    Expert Opin Investig Drugs; 2018 Feb; 27(2):199-207. PubMed ID: 29363343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists.
    Sandham DA; Adcock C; Bala K; Barker L; Brown Z; Dubois G; Budd D; Cox B; Fairhurst RA; Furegati M; Leblanc C; Manini J; Profit R; Reilly J; Stringer R; Schmidt A; Turner KL; Watson SJ; Willis J; Williams G; Wilson C
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4794-8. PubMed ID: 19592244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of sulphone-based CRTh2 antagonists.
    Buil MA; Calbet M; Castillo M; Castro J; Esteve C; Ferrer M; Forns P; González J; López S; Roberts RS; Sevilla S; Vidal B; Vidal L; Vilaseca P
    Eur J Med Chem; 2016 May; 113():102-33. PubMed ID: 26922232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of prostaglandin D2 receptor antagonist: discovery of highly potent antagonists.
    Torisu K; Kobayashi K; Iwahashi M; Nakai Y; Onoda T; Nagase T; Sugimoto I; Okada Y; Matsumoto R; Nanbu F; Ohuchida S; Nakai H; Masaaki Toda
    Bioorg Med Chem; 2004 Sep; 12(17):4685-700. PubMed ID: 15358295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.